Wave 80, Magnisense Partner in Infectious Disease Diagnostics
and Patient Monitoring
Collaboration to explore new ways of using magnetic detection
in high-performance enclosed-cartridge-format assays
San Francisco, California and Paris, France, March 5, 2009. Wave 80 Biosciences (www.wave80.com) and Magnisense (www.magnisense.com) today announced the establishment of a new strategic partnership to explore synergies between the companies’ industry-leading technology platforms, MIAtek® magnetic detection technology and SCATM assay cartridge technology.
Daniel Laser, Chief Executive Officer, Wave 80 said: “With its unique ability to scan a volumetric sampling region and the vast increase in the area per detectible particle compared to alternative magnetic detection methods, Magnisense’s MIAtek® magnetic detection technology is a breakthrough in clinical laboratory testing. Its robustness, sensitivity, speed, and dynamic range make MIAtek truly compelling for a broad range of assays.”
Luc Lenglet, Chief Executive Officer, Magnisense said: “By enhancing on-cartridge assay process control while eliminating the dynamic mechanical interface between cartridge and instrument, Wave 80’s SCATM technology is a major leap forward for cartridge-format clinical laboratory testing systems. The introduction of high-value clinical laboratory tests in a cost-effective enclosed-cartridge format will be a boon to patients, providers, and payers alike.”
The first phase of this collaboration, between Wave 80 and US-based scientists skilled in the MIAtek® technology, will center on diagnostics and patient monitoring for infectious disease. The work will be funded in part by a grant from the U.S. National Institute of Allergy and Infectious Disease, part of the National Institutes of Health.
About Wave 80
Wave 80 Biosciences is a research-driven medical technologies company developing high-performance molecular assay methods, novel techniques for leukocyte analysis and fractionation, and innovative clinical laboratory testing systems. Wave 80’s lead pipeline product is the EOSCAPE-HIV, an innovative compact-form-factor system for determination of HIV viral load in peripheral blood. Wave 80 is headquartered in San Francisco, California.
About Magnisense
Magnisense SA is a leading developer of magnetic based rapid diagnostics. The company’s unique MIAtek® technology leverages the unique superparamagnetic properties of nanometric sized particles which provides a highly sensitive result from a simple test. Magnisense is headquartered in Paris and has operations in Lyon, Moscow, Philadelphia, and Seattle.| Press and Analyst contacts: Andrew Lloyd & Associates - +44 1273 675 100 Andrew Lloyd – Neil Hunter allo@ala.com - neil@ala.com |